Last reviewed · How we verify
Tularemia — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Minocycline Hydrochloride | MINOCYCLINE | Rempex | Tetracycline-class Drug | 1971-01-01 | ||
| Vibramycin | doxycycline | Generic (originally Pfizer) | Tetracycline antibiotic | 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3 | 1967-01-01 | |
| Doxycyclin | Doxycyclin | Bulovka Hospital | 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3 | |||
| Minocyclin | Minocyclin | University of Southern California | 30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Tularemia
- Bulovka Hospital · 1 drug in Tularemia
- Generic (originally Pfizer) · 1 drug in Tularemia
- Rempex · 1 drug in Tularemia
- University of Southern California · 1 drug in Tularemia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Tularemia:
- Tularemia treatment updates — RSS
- Tularemia treatment updates — Atom
- Tularemia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Tularemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tularemia. Accessed 2026-06-10.
Related
- Tularemia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing